GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Resources Boya Bio-pharmaceutical Group Co Ltd (SZSE:300294) » Definitions » Debt-to-Equity

China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is China Resources Boya Bio-pharmaceutical Group Co Debt-to-Equity?

China Resources Boya Bio-pharmaceutical Group Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1 Mil. China Resources Boya Bio-pharmaceutical Group Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥24 Mil. China Resources Boya Bio-pharmaceutical Group Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥7,472 Mil. China Resources Boya Bio-pharmaceutical Group Co's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for China Resources Boya Bio-pharmaceutical Group Co's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of China Resources Boya Bio-pharmaceutical Group Co was 0.26. The lowest was 0.00. And the median was 0.06.

SZSE:300294's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

China Resources Boya Bio-pharmaceutical Group Co Debt-to-Equity Historical Data

The historical data trend for China Resources Boya Bio-pharmaceutical Group Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Boya Bio-pharmaceutical Group Co Debt-to-Equity Chart

China Resources Boya Bio-pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.08 0.01 0.01 -

China Resources Boya Bio-pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - - -

Competitive Comparison of China Resources Boya Bio-pharmaceutical Group Co's Debt-to-Equity

For the Biotechnology subindustry, China Resources Boya Bio-pharmaceutical Group Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Boya Bio-pharmaceutical Group Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Resources Boya Bio-pharmaceutical Group Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where China Resources Boya Bio-pharmaceutical Group Co's Debt-to-Equity falls into.



China Resources Boya Bio-pharmaceutical Group Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

China Resources Boya Bio-pharmaceutical Group Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

China Resources Boya Bio-pharmaceutical Group Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resources Boya Bio-pharmaceutical Group Co  (SZSE:300294) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


China Resources Boya Bio-pharmaceutical Group Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of China Resources Boya Bio-pharmaceutical Group Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Business Description

Traded in Other Exchanges
N/A
Address
Number 333, Huiquan Road, High-tech Industrial Park, Jiangxi Province, Fuzhou, CHN, 344000
China Resources Boya Bio-pharmaceutical Group Co Ltd is a China-based medical industry group that integrates biochemical drugs, chemical drugs, and active pharmaceutical ingredients. It is engaged in the provision of medical and health products and services. The product categories of the company include blood products, biochemical drugs, chemical medicines and others. Some of the company's blood products include human albumin, rabies immunoglobulin, intravenous human immunoglobulin and human fibrinogen.

China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Headlines

No Headlines